Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05307705
Title A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Eli Lilly and Company
Indications

Her2-receptor negative breast cancer

Advanced Solid Tumor

breast cancer

Therapies

Abemaciclib + Anastrozole + LOXO-783

Abemaciclib + Exemestane + LOXO-783

Abemaciclib + Letrozole + LOXO-783

LOXO-783 + Paclitaxel

Fulvestrant + LOXO-783

LOXO-783 + LY3484356

Abemaciclib + Fulvestrant + LOXO-783

Abemaciclib + LOXO-783 + LY3484356

LOXO-783

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST